Human immunodeficiency virus type 1 drug susceptibility during zidovudine (AZT) monotherapy compared with AZT plus 2',3'-dideoxyinosine or AZT plus 2',3'-dideoxycytidine combination therapy

Journal of Virology

Volumn 70, Issue 9, 1996, Pages 5922-5929

  Larder, Brendan A ^a   Kohli, Arinder ^a   Bloor, Stuart ^a   Kemp, Sharon D ^a   Harrigan, P Richard ^a   Schooley, Robert T ^b   Lange, Joep M A ^c   Pennington, Kevin N ^d   St Clair, Marty H ^d  

^a GLAXOSMITHKLINE   (United Kingdom)

^b UNIVERSITY OF COLORADO   (United States)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; ZALCITABINE; ZIDOVUDINE;

AMINO ACID SUBSTITUTION; ANTIVIRAL ACTIVITY; ARTICLE; DNA SEQUENCE; DRUG EFFECT; DRUG SENSITIVITY; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MONONUCLEAR CELL; PRIORITY JOURNAL; SITE DIRECTED MUTAGENESIS; VIRUS ISOLATION;

EID: 0029836432     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.70.9.5922-5929.1996     Document Type: Article

References (36)

1. Baizarini, J., A. Karlsson, M. L. Perez-Perez, M. J. Camarasa, W. G. Tarpley, and E. de Clerq. 1993. Treatment of human immunodeficiency virus type-1 (HIV-1) infected cells with combinations of HIV-1 specific inhibitors results in a different resistance pattern than does treatment with single-drug therapy. Virology 192:246-253.
2. Boucher, C. A., E. O'Sullivan, J. W. Mulder, C. Ramautarsing, P. Kellam, G. Darby, J. M. Lange, J. Goudsmit, and B. A. Larder. 1992. Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects. J. Infect. Dis. 165:105-110.
3. Byrnes, V. W., V. V. Sardana, W. A. Schleif, J. H. Condra, J. A. Waterbury, J. A. Wolfgang, W. J. Long, C. L. Schneider, A. J. Schlabach, B. S. Wolanski, D. J. Graham, L. Gotlib, A. Rhodes, D. L. Titus, E. Roth, O. M. Blahy, J. C. Quintero, S. Staszewski, and E. A. Emini. 1993. Comprehensive mutant enzyme and viral variant assessment of human immunodeficiency virus type 1 reverse transcriptase resistance to nonnucleoside inhibitors. Antimicrob. Agents Chemother. 37:1576-1579.
4. D'Aquila, R. T., V. A. Johnson, S. L. Welles, A. J. Japour, D. R. Kuritzkes, V. DeGruttola, P. S. Reichelderfer, R. W. Coombs, C. S. Crumpacker, J. O. Kahn, et al. 1995. Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. AIDS Clinical Trials Group Protocol 116B/117 Team and the Virology Committee Resistance Working Group. Ann. Intern. Med. 122:401-408.
5. De Jong, M. D., R. Schuurman, J. M. A. Lange, and C. A. B. Boucher. 1996. Replication of a pre-existing resistant HIV-1 subpopulation in vivo after introduction of a strong selective pressure. Antiviral Ther. 1:33-41.
6. Fitzgibbon, J. E., R. M. Howell, C. A. Haberzettl, S. J. Sperber, D. J. Gocke, and D. T. Dubin. 1992. Human immunodeficiency virus type 1 pol gene mutations which cause decreased susceptibility to 2′,3′-dideoxycytidine. Antimicrob. Agents Chemother. 36:153-157.
7. Gu, Z., Q. Gao, H. Fang, H. Salomon, M. A. Partiak, E. Goldberg, J. Cameron, and M. A. Wainberg. 1994. Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2′,3′-dideoxycytidine and 2′,3′-deoxythiacytidine. Antimicrob. Agents Chemother. 38:275-281.
8. Gu, Z., Q. Gao, X.-J. Li, and M. A. Wainberg. 1992. Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross resistance to 2′,3′-dideoxycytidine and 2′.3′dideoxy-3′-thiacytidine. J. Virol. 66:7128-7135.
9. Hammer, S., D. Katzenstein, M. Hughes, H. Grundacker, M. Hirsch, T. Merigan, for the ACTG 175 Study Team. 1995. Nucleosidc monotherapy (MT) vs combination therapy (CT) in HIV infected adults: a randomised double blind placebo controlled trial in persons with CD4 counts between 200 and 500 cells/mm3. Presented at the 5th European Conference on Clinical Aspects and Treatment of HIV Infection, Copenhagen, Denmark.
10. Iverson, A. K. N., R. W. Shafer, K. Wehrly, M. A. Winters, J. I. Mullins, B. Chesebro, and T. C. Merigan. 1996. Multidrug resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy. J. Virol. 70:1086-1090.
11. Jackson, J. B., R. W. Coombs, K. Sannerud, F. S. Rhame, and H. H. Balfour, Jr. 1988. Rapid and sensitive viral culture method for human immunodeficiency virus type 1. J. Clin. Microbiol. 26:1416-1418.
12. Japour, A. J., D. L. Mayers, V. A. Johnson, D. R. Kuritzkes, L. A. Beckett, J. M. Arduino, J. Lane, R. J. Black, P. S. Reichelderfer, R. T. D'Aquila, C. S. Crumpacker, The RV-43 Study Group, and The AIDS Clinical Trials Group Virology Committee Resistance Working Group. 1993. Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. Antimicrob. Agents Chemother. 37:1095-1101.
13. Kellam, P., C. A. B. Boucher, and B. A. Larder. 1992. Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high level resistance to zidovudinc. Proc. Natl. Acad. Sci. USA 89:1934-1938.
14. Kellam, P., C. A. B. Boucher, J. M. G. H. Tijnagel, and B. A. Larder. 1994. Zidovudine treatment results in the selection of human immunodeficiency virus type 1 variants whose genotypes confer increasing levels of drug resistance. J. Gen. Virol. 75:341-351.
15. Kellam, P., and B. A. Larder. 1994. Recombinant virus assay: a rapid, phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates. Antimicrob. Agents Chemother. 38:23-30.
16. Kellam, P., and B. A. Larder. 1995. Retroviral recombination can lead to linkage of reverse transcriptase mutations that confer increased zidovudine resistance. J. Virol. 69:669-774.
17. Larder, B. A., G. Darby, and D. D. Richman. 1989. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 243:1731-1734.
18. Larder, B. A., P. Kellam, and S. D. Kemp. 1991. Zidovudinc resistance predicted by direct detection of mutations in DNA from HIV-infected lymphocytes. AIDS 5:137-144.
19. Larder, B. A., P. Kellam, and S. D. Kemp. 1993. Convergent combination therapy can select viable multidrug resistant HIV-1 in vitro. Nature (London) 365:451-453.
20. Larder, B. A., and S. D. Kemp. 1989. Multiple mutations in HIV-1 reverse transcriptase confer high level resistance to zidovudine. Science 246:1155-1158.
21. Larder, B. A., A. Kohli, P. Kellam, S. D. Kemp, M. Kronick, and R. D. Henfrey. 1993. Quantitative detection of HIV-1 drug resistance mutations by automated DNA sequencing. Nature (London) 365:671-673.
22. Mellors, J., B. A. Larder, and R. Schinazi. 1995. Mutations associated with HIV-1 reverse transcriptasc and proteasc associated with drug resistance. Int. Antiviral News 3:8-13.
23. Najera, I., D. D. Richman, I. Olivares, J. M. Rojas, M. A. Perucho, R. Najera, and C. Lopez-Galindez. 1994. Natural occurrence of drug resistant mutations in the reverse transcriptase of human immunodeficiency virus type 1 isolates. AIDS Res. Hum. Retroviruses 10:1479-1488.
24. Richman, D. D. 1993. Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents. Antimicrob. Agents Chemother. 37:1207-1213.
25. Richman, D. D. 1994. Resistance, drug failure, and disease progression AIDS. Res. Hum. Retroviruses. 10:901-905.
26. Richman, D. D., D. Havlir, J. Corbeil, D. Looney, C. Ignatio, S. A. Spector, J. Sullivan, S. Cheeseman, K. Barringer, D. Pauletti, C-K. Shih, M. Myers, and J. Griffin. 1994. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J. Virol. 68:1660-1666.
27. Richman, D. D., T. C. Meng, S. A. Spector, M. A. Fischl, L. Resnick, and S. Lai. 1994. Resistance to AZT and ddC during long term combination therapy in patients with advanced infection with human immunodeficiency virus. J. Acquired Immune Defic. Syndr. 7:135-138.
28. Richman, D. D., C. K. Shih, I. Lowy, et al. 1991. Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture. Proc. Natl. Acad. Sci. USA 88:11241-11245.
29. Rooke, R., M. Tremblay, H. Soudeynes, L. De Stephano, X.-J. Yao, M. Fanning, J. S. G. Montaner, M. O'Shaughnessy, K. Gelman, C. Tsoukas, J. Gill, J. Reudy, and M. A. Wainberg. 1989. Isolation of drug resistant variants of HIV-1 from patients on long term zidovudine therapy. AIDS 3:411-415.
30. Schooley, R. T., C. Ramirez-Ronda, J. M. A. Lange, D. A. Cooper, J. Lavelle. L, Lefkowitz, M. Moore, B. A. Larder, M. St. Clair, P. Reiss, R. McKinnis, K. Pennington, P. R. Harrigan, I. Kinghorn, H. Steel, J. F. Rooney, and the Wellcome Resistance Study Collaborative Group. 1996. Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared to zidovudine monotherapy. J. Infect. Dis. 173:1354-1366.
31. Shafer, R. W., M. J. Kozal, M. A. Winters, A. K. Iversen, D. A. Katzenstein, M. V. Ragni, W. A. Meyer 3rd, P. Gupta, S. Rasheed, R. Coombs, et al. 1994 Combination therapy with zidovudine and didanosinc selects for drug resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations. J. Infect. Dis. 169:722-729.
32. Shirasaka, T., M. F. Kavlick, T. Ueno, W. Y. Gao, E. Kojima, M. L. Alcaide, S. Chokekijchai, B. M. Roy, E. Arnold, R. Yarchoan, et al. 1995. Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proc. Natl. Acad. Sci. USA 92:2398-2402.
33. ST. Clair, M. H., J. L. Martin, G. Tudor-Williams, M. C. Bach, C. L. Vavro, D. M. King, P. Kellam, S. D. Kemp, and B. A. Larder. 1991. Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science 253:1557-1559.
34. Volberding, P. 1995. The need for additional options in the treatment of human immunodeficiency virus infection. J. Infect. Dis. 171(Suppl. 2):S150-S154.
35. Yenni, P., on behalf of the DELTA International Co-ordinating Committee. 1995. Preliminary results of the European/Australian DELTA trial: based on data up to 31 May 1995. Presented at the 5th European Conference on Clinical Aspects and Treatment of HIV Infection, Copenhagen, Denmark.
36. Zhang, D., A. M. Caliendo, J. J. Eron, K. M. DeVore, J. C. Kaplan, M. S. Hirsch, and R. T. D'Aquila. 1994. Resistance to 2′,3′-dideoxycytidinc conferred by a mutation in codon 65 of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents. Chemother. 38:282-287.